EUVIMEDEUVIMED entdecken
Crossref

Dysregulation of PCSK9 via m6A-dependent epitranscriptomic programs fosters hepatocellular carcinoma progression

Wen-Lung Wang, Chih-Chieh Yen, Chia-Sheng Yen, Yu-Hsuan Huang, Hsuan-Yi Huang, Ju-Fei Chen, Yen-Yu Liu, Sih-Ting Wang, Yu-Tzu Liu, Mien-Chie Hung, Chia-Jui Yen

Cancer Letters · 2026

DOI: 10.1016/j.canlet.2026.218255 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2026. Verfasst von Wen-Lung Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 701401, Taiwan. Hauptthemen laut MEDLINE: Adenosine, Carcinoma, Hepatocellular, Epitranscriptome, Liver Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Cheng Kung University Hospital, National Science and Technology Council, National Cheng Kung University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PCSK9, besides its established role in cholesterol metabolism in the liver, has recently emerged as a tumor-promoting gene in various types of cancer including hepatocellular carcinoma (HCC). However, the regulatory pathways governing oncogenic PCSK9 in HCC remain poorly understood, particularly those involving epitranscriptomic modifications. Here, we identify PCSK9 as a novel mRNA target of METTL3 in HCC. Furthermore, METTL3 promotes tumor cell growth by upregulating PCSK9 mRNA through m6A methylation in the 3' UTR. Additionally, IGF2BP3 exerts its m6A reading function to maintain PCSK9 mRNA stability in an m6A-dependent manner, thereby fostering the capacity of tumor growth. Moreover, ILF3 interacts with IGF2BP3 to collaboratively enhance PCSK9 mRNA stability and ultimately contributes to tumor growth. The METTL3-IGF2BP3-ILF3-PCSK9 signaling pathway is additionally confirmed in HCC patient cohorts. In summary, our findings highlight that PCSK9 is controlled by m6A-dependent METTL3-IGF2BP3-ILF3 epitranscriptomic programs and contributes to HCC progression. The study provides a rationale for repurposing PCSK9-depleting therapeutics into a potential antitumor treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenosineCarcinoma, HepatocellularEpitranscriptomeLiver NeoplasmsMethyltransferasesProprotein Convertase 9AnimalsHumansMiceCell Line, TumorDisease ProgressionEpitranscriptomicsGene Expression Regulation, NeoplasticRNA MethylationRNA, MessengerRNA-Binding ProteinsSignal Transduction

Stichwörter der Autor:innen

Epitranscriptomic programsHCCPCSK9m(6)A

Substanzen

AdenosineMethyltransferasesMETTL3 protein, humanPCSK9 protein, humanProprotein Convertase 9RNA, MessengerRNA-Binding Proteins

Autor:innen und Institutionen

  • Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 701401, Taiwan.
  • Division of General Surgery, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, 813414, Taiwan; Department of Nursing, Meiho University, Pingtung, 912009, Taiwan.
  • Division of Colorectal Surgery, Department of Surgery, Chi Mei Medical Center, Tainan, 71004, Taiwan; Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, 70457, Taiwan.
  • Graduate Institute of Biomedical Sciences, China Medical University, Taichung, 406040, Taiwan; Institute of Biochemistry and Molecular Biology, China Medical University, Taichung, 406040, Taiwan; Research Center for Can…
  • Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 701401, Taiwan; National Cheng Kung University Hospital Cancer Center, Tainan, 70403, Taiwan.…

Förderung

  • National Cheng Kung University Hospital
  • National Science and Technology Council
  • National Cheng Kung University
  • Ministry of Science and Technology, Taiwan

Zitieren

APA

Wang, W. L., Yen, C. C., Yen, C. S., Huang, Y. H., Huang, H. Y., Chen, J. F., Liu, Y. Y., Wang, S. T., Liu, Y. T., Hung, M. C., & Yen, C. J. (2026). Dysregulation of PCSK9 via m6A-dependent epitranscriptomic programs fosters hepatocellular carcinoma progression. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218255

Vancouver

Wang WL, Yen CC, Yen CS, Huang YH, Huang HY, Chen JF, et al. Dysregulation of PCSK9 via m6A-dependent epitranscriptomic programs fosters hepatocellular carcinoma progression. Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218255

BibTeX
@article{Wang2026,
  author = {Wang, Wen-Lung and Yen, Chih-Chieh and Yen, Chia-Sheng and Huang, Yu-Hsuan and Huang, Hsuan-Yi and Chen, Ju-Fei and Liu, Yen-Yu and Wang, Sih-Ting and Liu, Yu-Tzu and Hung, Mien-Chie and Yen, Chia-Jui},
  title = {Dysregulation of PCSK9 via m6A-dependent epitranscriptomic programs fosters hepatocellular carcinoma progression},
  journal = {Cancer Letters},
  year = {2026},
  doi = {10.1016/j.canlet.2026.218255}
}
Kostenlos starten →